Strides Pharma Science

Strides Pharma Science Equity Growth

The Year-over-Year Equity Growth of Strides Pharma Science (STAR.NS) as of Nov 18, 2026 is 20.05 %. In the previous year, Year-over-Year Equity Growth was -3.92 % — a change of -611.74% (higher).

Equity Growth

20.05 %

YoY

-611.74%

Last updated:

Year-over-Year Equity Growth of Strides Pharma Science is 2025 20.05 % . Year-over-Year Equity Growth of Strides Pharma Science was 2024 -3.92 % . It decreases by -611.74% higher compared to the previous year.

The Strides Pharma Science Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-10.54 INR
Jan 1, 2019
7.51 INR
Jan 1, 2020
-4.58 INR
Jan 1, 2021
9.86 INR
Jan 1, 2022
-15.04 INR
Jan 1, 2023
-6.23 INR
Jan 1, 2024
-3.92 INR
Jan 1, 2025
20.05 INR
The Strides Pharma Science Equity Growth history
YEAREquity GrowthYoY
20.05 %-611.74%
-3.92 %-37.08%
-6.23 %-58.58%
-15.04 %-252.43%
9.86 %-315.39%
-4.58 %-160.99%
7.51 %-171.26%
-10.54 %-391.75%
3.61 %-97.22%
129.96 %+778.16%
14.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Year-over-Year Equity Growth of Strides Pharma Science is 20.05 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Strides Pharma Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Strides Pharma Science

All Key Metrics — Strides Pharma Science